P
ProHub
English 简体中文 繁體中文
Medium M&A Growth Strategy Revenue Analysis

Drugs “R” Us

#Pharma #Retail
ProHub Comment

This is a structured M&A case requiring candidates to build a revenue-focused framework and perform quantitative analysis. The key insight is recognizing that the acquisition adds only ~$1.8B in pharmaceutical revenue against a target of ~$16.1B (20% growth on RX Co's ~$14B baseline), making the deal insufficient on its own. Strong candidates distinguish between total US stores and NW region stores, explore revenue sources (RX vs. Front-of-House Merchandise), and identify strategic risks beyond pure financials.

Estimated Time 15 minutes
Difficulty Medium
Source Duke
50 / 100
Your client is RX Co, a pharmacy retailer with stores across the United States. To bolster their presence in the Pacific Northwest, they are in talks with Drug Corp to purchase retail assets in the region. Though the acquisition seems sound, the RX Co CEO wants to be sure that the transaction will help them achieve growth. Can you help the company evaluate the deal?

Clarifying Information

  1. RX Co aims to grow annual revenue by 20% from current levels. They want this to happen the first year after the acquisition is complete. Assume the acquisition can be completed and the assets operational in one year.